To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is a phase II open-label, multicentre, randomized trial. The study assesses the
treatment of postmenopausal patients with hormone receptor positive/HER2 positive early
breast cancer with neoadjuvant palbociclib in combination with hormonal therapy and HER2
blockade, versus the treatment with paclitaxel in combination with HER2 blockade.